NYSE:PKI - PerkinElmer Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $109.20
  • Forecasted Upside: -15.52 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$129.26
▲ +1.76 (1.38%)
1 month | 3 months | 12 months
Get New PerkinElmer Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PKI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PKI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$109.20
▼ -15.52% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for PerkinElmer in the last 3 months. The average price target is $109.20, with a high forecast of $193.00 and a low forecast of $45.00. The average price target represents a -15.52% upside from the last price of $129.26.
Buy
The current consensus among 14 contributing investment analysts is to buy stock in PerkinElmer. This rating has held steady since June 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/27/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2020The Goldman Sachs GroupInitiated CoverageBuy$50.00Low
i
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$150.00Medium
i
11/9/2020Needham & Company LLCBoost Price TargetBuy$139.00 ➝ $193.00High
i
Rating by Stephen Unger at Needham & Company LLC
10/29/2020Smith Barney CitigroupBoost Price Target$120.00 ➝ $140.00Low
i
10/29/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$130.00 ➝ $140.00Low
i
10/29/2020Robert W. BairdBoost Price TargetOutperform$137.00 ➝ $151.00High
i
9/11/2020Needham & Company LLCUpgradeHold ➝ Buy$139.00High
i
Rating by Stephen Unger at Needham & Company LLC
8/10/2020BMO Capital MarketsBoost Price TargetOutperform$44.00 ➝ $45.00Low
i
7/29/2020JPMorgan Chase & Co.Boost Price TargetNeutral$85.00 ➝ $105.00High
i
7/29/2020Stifel NicolausBoost Price TargetBuy$95.00 ➝ $125.00High
i
7/29/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$105.00 ➝ $130.00High
i
7/29/2020CfraUpgradeHold ➝ BuyHigh
i
7/13/2020Needham & Company LLCInitiated CoverageHoldHigh
i
Rating by Stephen Unger at Needham & Company LLC
5/7/2020UBS GroupBoost Price TargetNeutral$95.00 ➝ $96.00Low
i
5/6/2020Robert W. BairdBoost Price TargetOutperform$94.00 ➝ $99.00Low
i
5/6/2020CfraLower Price TargetHold$100.00 ➝ $94.00Low
i
5/6/2020JPMorgan Chase & Co.Boost Price TargetNeutral$80.00 ➝ $85.00Medium
i
4/28/2020UBS GroupLower Price TargetNeutral$100.00 ➝ $95.00Low
i
4/20/2020CitigroupBoost Price TargetNeutral$70.00 ➝ $85.00Low
i
4/2/2020JPMorgan Chase & Co.Lower Price TargetOverweight$49.00 ➝ $45.00High
i
4/2/2020Stifel NicolausLower Price TargetBuy$102.00 ➝ $80.00Low
i
3/30/2020Wells Fargo & CompanyLower Price TargetEqual Weight$100.00 ➝ $80.00Low
i
3/26/2020BarclaysLower Price TargetEqual Weight$100.00 ➝ $94.00Medium
i
3/20/2020CitigroupLower Price TargetNeutral$100.00 ➝ $70.00Low
i
1/28/2020UBS GroupBoost Price TargetNeutral$92.00 ➝ $100.00High
i
1/14/2020TD SecuritiesBoost Price TargetBuy$54.00 ➝ $56.00Medium
i
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$105.00Low
i
1/6/2020CitigroupInitiated CoverageNeutral$100.00Medium
i
1/3/2020Needham & Company LLCInitiated CoverageHold$79.00Medium
i
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$89.00 ➝ $114.00High
i
11/21/2019Stifel NicolausReiterated RatingBuyLow
i
11/14/2019Stifel NicolausInitiated CoverageBuy$102.00High
i
11/5/2019Raymond JamesReiterated RatingBuy ➝ Average$51.00Low
i
10/31/2019Needham & Company LLCReiterated RatingHoldHigh
i
10/31/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$104.00 ➝ $89.00High
i
10/18/2019UBS GroupLower Price TargetNeutral$101.00 ➝ $92.00Low
i
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$105.00Low
i
7/30/2019UBS GroupBoost Price TargetNeutral$99.00 ➝ $101.00High
i
Rating by Daniel Brennan at UBS Group AG
7/19/2019Wood & CompanyReiterated RatingAverage$49.00Medium
i
7/10/2019Raymond JamesInitiated CoverageOutperformLow
i
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
i
5/3/2019Royal Bank of CanadaReiterated RatingHold$41.00Low
i
4/9/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00High
i
2/2/2019UBS GroupSet Price TargetHold$92.00Low
i
Rating by Daniel Brennan at UBS Group AG
2/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$104.00Medium
i
1/16/2019DesjardinsReiterated RatingBuy ➝ Average$45.00Low
i
1/10/2019CIBCReiterated RatingBuy ➝ Average$44.50Medium
i
1/6/2019CowenReiterated RatingHold$85.00Low
i
1/3/2019Morgan StanleyLower Price TargetOverweight ➝ Overweight$100.00 ➝ $86.00Low
i
1/2/2019Needham & Company LLCInitiated CoverageHold ➝ Hold$79.00High
i
11/2/2018Janney Montgomery ScottDowngradeBuy ➝ NeutralMedium
i
10/10/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$95.00 ➝ $100.00High
i
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$100.00Low
i
9/10/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$88.00 ➝ $93.00Low
i
9/5/2018BarclaysUpgradeUnderweight ➝ Equal Weight$79.00 ➝ $90.00Low
i
8/30/2018Cleveland ResearchUpgradeNeutral ➝ BuyMedium
i
8/2/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$83.00 ➝ $86.00Low
i
Rating by Derik De Bruin at Bank of America Co.
8/2/2018CowenReiterated RatingHold$85.00Low
i
8/2/2018Robert W. BairdReiterated RatingBuy$89.00Low
i
8/2/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$73.00 ➝ $79.00High
i
8/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $95.00High
i
5/1/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $90.00High
i
5/1/2018Bank of AmericaLower Price TargetNeutral ➝ Hold$86.00 ➝ $83.00High
i
Rating by Derik De Bruin at Bank of America Co.
5/1/2018Robert W. BairdLower Price TargetOutperform ➝ Outperform$88.00 ➝ $82.00High
i
5/1/2018Janney Montgomery ScottLower Price TargetBuy ➝ Fair Value$92.00 ➝ $73.36High
i
4/11/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$89.00 ➝ $85.00Low
i
4/9/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$85.00 ➝ $80.00Low
i
1/26/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$69.00 ➝ $73.00Low
i
1/26/2018CowenReiterated RatingHold$84.00Low
i
1/26/2018Robert W. BairdReiterated RatingBuy$88.00Medium
i
1/3/2018Evercore ISIInitiated CoverageIn-Line$77.00Low
i
12/19/2017Bank of AmericaUpgradeUnderperform ➝ Neutral$78.00Low
i
Rating by Derik De Bruin at Bank of America Co.
11/3/2017Morgan StanleyBoost Price TargetOverweight$77.00 ➝ $78.00N/A
i
11/3/2017Robert W. BairdBoost Price TargetOutperform$75.00 ➝ $78.00N/A
i
10/20/2017Jefferies Financial GroupReiterated RatingHold$70.00N/A
i
10/20/2017Robert W. BairdReiterated RatingBuy$72.00N/A
i
10/6/2017Morgan StanleyReiterated RatingOverweight$79.00 ➝ $77.00N/A
i
9/26/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$67.00Low
i
9/26/2017CitigroupReiterated RatingBuy$74.00 ➝ $80.00Low
i
9/1/2017CowenReiterated RatingHold$70.00Low
i
8/7/2017CitigroupBoost Price TargetBuy$67.00 ➝ $74.00Medium
i
8/4/2017Piper Jaffray CompaniesReiterated RatingBuy$81.00Medium
i
7/25/2017Piper Jaffray CompaniesBoost Price TargetOverweight$80.00Medium
i
7/16/2017Cantor FitzgeraldReiterated RatingHoldLow
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$72.00Low
i
7/10/2017Morgan StanleyReiterated RatingOverweight$73.00 ➝ $79.00Low
i
6/22/2017Evercore ISIReiterated RatingIn-Line$62.50 ➝ $68.00Low
i
6/21/2017Cantor FitzgeraldReiterated RatingNeutralLow
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
6/20/2017Jefferies Financial GroupReiterated RatingHold$58.00 ➝ $69.00Medium
i
6/20/2017CowenReiterated RatingMarket Perform$61.00 ➝ $70.00Low
i
6/19/2017Cantor FitzgeraldSet Price TargetHold$65.00High
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
5/15/2017Jefferies Financial GroupReiterated RatingHold$49.00Low
i
5/15/2017Cantor FitzgeraldReiterated RatingHold$65.00Low
i
Rating by B. Brokmeier at Cantor Fitzgerald
5/6/2017BarclaysSet Price TargetSell$55.00Low
i
Rating by Jack Meehan at Barclays PLC
5/5/2017Cantor FitzgeraldReiterated RatingHold$65.00High
i
Rating by B. Brokmeier at Cantor Fitzgerald
5/5/2017Jefferies Financial GroupReiterated RatingHold$49.00High
i
4/19/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$60.00Low
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
4/7/2017CitigroupBoost Price TargetBuy$57.00 ➝ $67.00Low
i
3/27/2017Janney Montgomery ScottUpgradeNeutral ➝ BuyMedium
i
2/5/2017BTIG ResearchReiterated RatingHoldN/A
i
2/3/2017Bank of AmericaDowngradeNeutral ➝ Underperform$48.00N/A
i
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$55.00N/A
i
12/25/2016Cantor FitzgeraldSet Price TargetBuy$60.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
11/8/2016BarclaysReiterated RatingSell$50.00N/A
i
9/22/2016UBS GroupReiterated RatingBuy$56.00 ➝ $61.00N/A
i
Rating by Jon Groberg at UBS Group AG
8/5/2016JPMorgan Chase & Co.Boost Price TargetNeutral$52.00 ➝ $55.00N/A
i
8/5/2016Jefferies Financial GroupBoost Price TargetHold$52.00 ➝ $55.00N/A
i
8/5/2016Morgan StanleySet Price TargetBuy$61.00N/A
i
Rating by Steve Beuchaw at Morgan Stanley
8/5/2016BarclaysBoost Price TargetUnderweight$50.00 ➝ $52.00N/A
i
Rating by Jack Meehan at Barclays PLC
8/5/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Dane Leone at BTIG Research
8/5/2016MizuhoDowngradeBuy ➝ Neutral$56.00N/A
i
7/22/2016BTIG ResearchInitiated CoverageNeutralN/A
i
Rating by Dane Leone at BTIG Research
5/8/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Steve Beuchaw at Morgan Stanley
5/8/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Jeff Elliott at Robert W. Baird
5/6/2016Cantor FitzgeraldReiterated RatingBuy$60.00N/A
i
5/6/2016Stifel NicolausBoost Price TargetBuy$51.00 ➝ $59.00N/A
i
5/6/2016MizuhoBoost Price TargetBuy$52.00 ➝ $56.00N/A
i
4/5/2016Bank of AmericaDowngradeBuy ➝ Neutral$52.00N/A
i
3/24/2016UBS GroupReiterated RatingBuy$56.00N/A
i
3/23/2016The Goldman Sachs GroupBoost Price Target$42.00N/A
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
3/1/2016BarclaysInitiated CoverageUnderweight$46.00N/A
i
2/8/2016Jefferies Financial GroupReiterated RatingHold$50.00 ➝ $47.00N/A
i
2/8/2016Cantor FitzgeraldReiterated RatingBuy$59.00N/A
i
2/7/2016BTIG ResearchReiterated RatingNeutralN/A
i
2/5/2016Jefferies Financial GroupLower Price TargetHold$50.00 ➝ $47.00N/A
i
2/5/2016The Goldman Sachs GroupLower Price TargetSell$41.00 ➝ $40.00N/A
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
2/5/2016MizuhoReiterated RatingBuy ➝ Buy$58.00 ➝ $52.00N/A
i
2/5/2016Stifel NicolausLower Price TargetBuy$60.00 ➝ $51.00N/A
i
1/7/2016CowenDowngradeOutperform ➝ Market Perform$55.00N/A
i
1/6/2016Deutsche Bank AktiengesellschaftInitiated CoverageHold$51.00N/A
i
12/8/2015The Goldman Sachs GroupDowngradeNeutral ➝ Sell$50.00 ➝ $44.00N/A
i
12/3/2015WedbushDowngradeOutperform ➝ Neutral$56.00N/A
i
Rating by Z. Khurshid at Wedbush
(Data available from 11/28/2015 forward)
PerkinElmer logo
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $129.26
$127.62
$129.32

50 Day Range

MA: $128.94
$122.05
$141.30

52 Week Range

Now: $129.26
$62.91
$142.65

Volume

283,812 shs

Average Volume

913,300 shs

Market Capitalization

$14.47 billion

P/E Ratio

49.15

Dividend Yield

0.22%

Beta

1.3